Ryan Fukushima Sells 3,500 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 3,500 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00. Following the transaction, the chief operating officer now directly owns 1,003,707 shares of the company's stock, valued at approximately $40,379,132.61. This represents a 0.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Stock Down 12.0 %

NASDAQ TEM traded down $4.66 on Wednesday, reaching $34.29. 7,396,915 shares of the company's stock traded hands, compared to its average volume of 1,521,735. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49. The stock has a 50-day moving average price of $52.24. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently made changes to their positions in the business. NEA Management Company LLC bought a new position in Tempus AI during the 2nd quarter worth approximately $160,048,000. Novo Holdings A S purchased a new position in shares of Tempus AI in the second quarter worth $142,605,000. Revolution Growth Management Company Inc. bought a new stake in Tempus AI during the 2nd quarter valued at $128,133,000. ARK Investment Management LLC boosted its position in Tempus AI by 355.0% during the 3rd quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company's stock valued at $134,604,000 after buying an additional 1,855,459 shares during the period. Finally, Alphabet Inc. bought a new stake in Tempus AI in the 2nd quarter worth $54,289,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Wall Street Analysts Forecast Growth

TEM has been the topic of several research analyst reports. Piper Sandler reaffirmed a "neutral" rating and issued a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital raised their price target on Tempus AI from $48.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, October 15th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They set a "buy" rating and a $74.00 price target for the company. Bank of America upped their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research report on Friday, December 13th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a "buy" rating to a "hold" rating and lifted their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.